The Gross Margin of Jounce Therapeutics Inc (JNCE) is
7775.20%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2022-12-31 |
7775.20%
|
| Ticker |
Name |
Value |
|
ANAB
|
AnaptysBio, Inc.
|
7775.20%
|
|
APLT
|
Applied Therapeutics Inc
|
7775.20%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
ACET
|
ADICET Bio, Inc.
|
7775.20%
|
|
AMGN
|
Amgen Inc
|
70.78%
|
|
RIGL
|
Rigel Pharmaceuticals, Inc.
|
93.33%
|
|
AGEN
|
Agenus Inc
|
99.11%
|
|
AUTL
|
Autolus Therapeutics PLC
|
-26.10%
|
|
SYRS
|
Syros Pharmaceuticals Inc
|
7775.20%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
CNTG
|
Centogene NV
|
36.46%
|
|
RAPT
|
RAPT Therapeutics, Inc
|
7775.20%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
XOMA
|
XOMA Royalty Corporation
|
100.00%
|
|
GERN
|
Geron Corporation
|
97.42%
|
|
AVRO
|
AVROBIO Inc
|
7775.20%
|
|
BCYC
|
Bicycle Therapeutics PLC
|
7775.20%
|
|
ETNB
|
89bio Inc
|
7775.20%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
NLTX
|
Neoleukin Therapeutics Inc
|
7775.20%
|
|
INZY
|
Inozyme Pharma Inc
|
7775.20%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
SELB
|
Selecta Biosciences Inc
|
7775.20%
|
|
SPRO
|
Spero Therapeutics, Inc.
|
7775.20%
|
|
XBIT
|
XBiotech Inc
|
83.79%
|
|
DTIL
|
Precision Biosciences, Inc
|
7775.20%
|
|
IDYA
|
IDEAYA Biosciences, Inc.
|
7775.20%
|
|
CTMX
|
CytomX Therapeutics, Inc.
|
7775.20%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
HARP
|
Harpoon Therapeutics Inc
|
7775.20%
|
|
SMMT
|
Summit Therapeutics Inc.
|
99.95%
|
|
SQZ
|
SQZ Biotechnologies Co
|
7775.20%
|
|
ALDX
|
Aldeyra Therapeutics Inc
|
7775.20%
|
|
CRNX
|
Crinetics Pharmaceuticals, Inc.
|
86.02%
|